Allegations that drugmakers are raising prices in anticipation of healthcare legislation that may reduce pharmaceutical costs or curb growth have led several House committee leaders to request a Government Accountability Office (GAO) investigation on recent price trends. Three House Ways and Means Committee members, Chairman Charles Rangel (D-N.Y.), Reps. Pete Stark (D-Calif.) and John Lewis (D-Ga.), and House Energy and Commerce Committee Chairman Henry Waxman (D-Calif.) requested the report in a Nov. 17 letter.
Drug Industry Daily